Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy

Overview

Journal Pathogens

Date 2022 Oct 27

PMID 36297203

Authors

Ee Wern Tan

Noraini Abd-Aziz

Chit Laa Poh

Kuan Onn Tan

Affiliations

Soon will be listed here.

Abstract

Cancer is among the major leading causes of mortality globally, and chemotherapy is currently one of the most effective cancer therapies. Unfortunately, chemotherapy is invariably accompanied by dose-dependent cytotoxic side effects. Recently, genetically engineered adenoviruses emerged as an alternative gene therapy approach targeting cancers. This review focuses on the characteristics of genetically modified adenovirus and oncology clinical studies using adenovirus-mediated gene therapy strategies. In addition, modulation of the tumor biology and the tumor microenvironment as well as the immunological responses associated with adenovirus-mediate cancer therapy are discussed.

Citing Articles

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.

Park A, Lee J J Microbiol. 2024; 62(7):491-509.

PMID: 39037484 DOI: 10.1007/s12275-024-00159-4.

Harnessing the potential of CD40 agonism in cancer therapy.

Zhou Y, Richmond A, Yan C Cytokine Growth Factor Rev. 2023; 75:40-56.

PMID: 38102001 PMC: 10922420. DOI: 10.1016/j.cytogfr.2023.11.002.

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.

Siak P, Heng W, Teoh S, Lwin Y, Cheah S J Transl Med. 2023; 21(1):786.

PMID: 37932756 PMC: 10629096. DOI: 10.1186/s12967-023-04673-8.

The role of Epstein-Barr virus in nasopharyngeal carcinoma.

Su Z, Siak P, Leong C, Cheah S Front Microbiol. 2023; 14:1116143.

PMID: 36846758 PMC: 9947861. DOI: 10.3389/fmicb.2023.1116143.

References

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Leen A, Christin A, Khalil M, Weiss H, Gee A, Brenner M . Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2007; 82(1):546-54. PMC: 2224388. DOI: 10.1128/JVI.01689-07. View

Thomas D, Radhakrishnan P . Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019; 18(1):14. PMC: 6341551. DOI: 10.1186/s12943-018-0927-5. View

Nguyen K, Vrabel M, Mantooth S, Hopkins J, Wagner E, Gabaldon T . Localized Interleukin-12 for Cancer Immunotherapy. Front Immunol. 2020; 11:575597. PMC: 7593768. DOI: 10.3389/fimmu.2020.575597. View

Lynch 3rd J, Fishbein M, Echavarria M . Adenovirus. Semin Respir Crit Care Med. 2011; 32(4):494-511. DOI: 10.1055/s-0031-1283287. View

Kock A, Larsson K, Bergqvist F, Eissler N, Elfman L, Raouf J . Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth. EBioMedicine. 2018; 32:84-92. PMC: 6021299. DOI: 10.1016/j.ebiom.2018.05.008. View

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S . Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014; 11(9):509-24. DOI: 10.1038/nrclinonc.2014.111. View

Oostrum J, Smith P, Mohraz M, Burnett R . The structure of the adenovirus capsid. III. Hexon packing determined from electron micrographs of capsid fragments. J Mol Biol. 1987; 198(1):73-89. DOI: 10.1016/0022-2836(87)90459-1. View

Wang P, Li X, Wang J, Gao D, Li Y, Li H . Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017; 8(1):1395. PMC: 5680234. DOI: 10.1038/s41467-017-01385-8. View

10.

Brunetti-Pierri N, Ng P . Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum Mol Genet. 2011; 20(R1):R7-13. PMC: 3095052. DOI: 10.1093/hmg/ddr143. View

11.

Nayyar G, Chu Y, Cairo M . Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Front Oncol. 2019; 9:51. PMC: 6378304. DOI: 10.3389/fonc.2019.00051. View

12.

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I . Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013; 19(10):2734-44. DOI: 10.1158/1078-0432.CCR-12-2546. View

13.

Shiomi A, Usui T . Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm. 2015; 2015:568543. PMC: 4370199. DOI: 10.1155/2015/568543. View

14.

Seregin S, Aldhamen Y, Appledorn D, Hartman Z, Schuldt N, Scott J . Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood. 2010; 116(10):1669-77. PMC: 2947391. DOI: 10.1182/blood-2010-03-276949. View

15.

Korniluk A, Kemona H, Dymicka-Piekarska V . Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014; 35(10):9447-57. PMC: 4213374. DOI: 10.1007/s13277-014-2407-x. View

16.

Wold W, Toth K . Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013; 13(6):421-33. PMC: 4507798. DOI: 10.2174/1566523213666131125095046. View

17.

Sprague L, Braidwood L, Conner J, Cassady K, Benencia F, Cripe T . Please stand by: how oncolytic viruses impact bystander cells. Future Virol. 2018; 13(9):671-680. PMC: 6219440. DOI: 10.2217/fvl-2018-0068. View

18.

Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S . Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004; 64(9):3281-7. DOI: 10.1158/0008-5472.can-03-3911. View

19.

Kakarla S, Song X, Gottschalk S . Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy. 2012; 4(11):1129-38. PMC: 3568630. DOI: 10.2217/imt.12.112. View

20.

Cerullo V, Koski A, Vaha-Koskela M, Hemminki A . Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res. 2012; 115:265-318. DOI: 10.1016/B978-0-12-398342-8.00008-2. View